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E-cadherin expression in the head and neck epithelium is essential for the morphogenesis and homeostasis of epithelial tissues.
The cadherin-mediated cell-cell contacts are required for the anchorage-dependent growth of epithelial cells. Further, survival and
proliferation require physical tethering created by proper cell-cell adhesion. Otherwise, the squamous epithelial cells will undergo
programmed cell death. Head and neck cancers can escape from anoikis and enter into the epithelial-mesenchymal transition
stages via the modulation of E-cadherin expression with epigenetic mechanisms. At epigenetic level, gene expression control is not
dependent on the DNA sequence. In the context of E-cadherin regulation in head and neck cancers, 2 major mechanisms including
de novo promoter hypermethylation and microRNA dysregulation are most extensively studied. Both of them control E-cadherin
expression at transcription level and subsequently hinder the overall E-cadherin protein level in the head and neck cancer cells.
Increasing evidence suggested that microRNAmediated E-cadherin expression in the head and neck cancers by directly/indirectly
targeting the transcription suppressors of E-cadherin, ZEB1 and ZEB2.
1. Introduction
Head and neck cancers could be developed from multiple
sites in the head and neck regions including nasopharynx,
oral cavity, oropharynx, larynx, and pharynx. It is the sixth
most common cancer worldwide and is the fourth most
common cancer in the male population in Europe [1].
Head and neck cancer is a multifactorial disease. Well-
known risk factors include tobacco and alcohol consumption
[2]. Epidemiology data suggested that there is a significant
increase in the risk for cancer development in the group
of smokers and drinkers, especially in young adults [3].
In particular geographic regions, the cancers from the oral
cavity and oropharyngeal regions are linkedwith the chewing
of tobacco or betel nut [4, 5]. Head and neck regions are
subjected to “field cancerization.” Early genetic changes could
possibly be reverted if the risk factors are removed in the
early stages [6, 7]. Patients with precancerous lesions such
as leukoplakia and erythroplakia have a high probability to
progress to carcinomawithout early diagnosis. Histologically,
squamous cell carcinoma is the major clinical presentation
of head and neck cancers. The prognosis of head and neck
cancer is poor especially when regional migration to cervical
lymph nodes and metastasis to distant organs are presented.
The migration and invasion of the head and neck cancer
are sequential processes. In oral tongue cancer, the risk for
lymphatic metastasis increased with the tumor volume [8].
It is evidenced that the tumor depth is a predictive factor
for cervical metastasis [9]. Further, the relevance between
regional lymph nodemigration of head and neck cancers and
poor prognosis is documented in hypopharyngeal carcinoma
patients in which patients with high positive lymph nodes
ratio closely tend to have poorer survival [10].
2. E-Cadherin Dysregulation in
Head and Neck Cancers
Epithelial cadherin (E-cadherin or cadherin 1) is a trans-
membrane glycoprotein that functions as cell adhesion
molecule (CAM). The gene encoding E-cadherin (CDH1)
located at chromosome 16q22.1, a common hotspot of genetic
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abbreviations such as loss of heterozygosity (LOH) and
mutations. Structurally, the E-cadherin protein contains five
extracellular cadherin repeats, a transmembrane region, and
a highly conserved cytoplasmic tail. It is a calcium-dependent
molecule involved in cell-cell adhesion, cell dissociation, and
cell motility. The transmembrane glycoprotein establishes
homophilic interactions with adjacent E-cadherin molecules
forming the epithelial junctional complexes, which mediate
the cell-cell adhesion in the epithelial tissues [11]. On the
other hand, the cytoplasmic tail forms a link with the actin
cytoskeleton of the cells [12].
E-cadherin expression is ubiquitous in normal stratified
squamous epithelium of the oral cavity and oropharynx. E-
cadherin suppressed head and neck epithelial cancer cells
escape from contact-dependent growth and develop migra-
tory phenotype with low differentiation stage, suggesting that
E-cadherin has the potential to contribute to the transfor-
mation steps. It has been hypothesized that the E-cadherin
negative cells are dissociated at the invasive fronts at the
late progressive stages of oral tongue cancer development
resulting in themetastasis to the regional lymphnodes [13]. In
the in vitromodel, cell lines expressing E-cadherinwill appear
as cuboidal morphology in well-differentiated cell lines and
formed cobblestone colonies. In poorly differentiated cell
lines, the cells will be shown as spindle-shaped with weak or
no E-cadherin expression [14].
E-cadherin expression level is associated with the behav-
ior of the cancers cells in the animal models and usually
accompanied with high invasion ability. Cell lines losing E-
cadherin expression displayed an increase in the invasive
capacity. The oral tongue cancer cell line treated with human
monoclonal antibodies will form highly invasive clones [13].
Similar to the cell line models, E-cadherin expression in
the primary oral tongue cancer tissue is correlated with the
cancer grading and is an indicator of poor prognosis for oral
tongue cancer patients [15]. Further, low E-cadherin expres-
sion is an indicator of late cervical lymph node metastasis
and is a poor prognostic factor for the overall survival of
oral squamous cell carcinoma patients [16, 17]. Accumulating
data on clinical specimens provided mounting evidence for
the use of E-cadherin as an independent risk factor for oral
tongue cancer patients [17]. The loss of homophilic cell-
cell adhesive property in the E-cadherin suppressed cells
will lead to the development of invasive phenotype. If the
loss is a consequence of epigenetic aberration, the acquired
invasive phenotype could possibly be reversed with the use
of epigenetic drugs [18].
3. Epithelial-Mesenchymal Transition
(EMT) and E-Cadherin
Epithelial head and neck cancer cells could acquire the ability
to migrate and invade the surrounding tissues. As the cells
move into the lymphatic system, they could be detected in the
regional lymph nodes via route of peripheral lymphovascular
channels. This process is generally regarded as epithelial-
mesenchymal transition (EMT) accompanied by the con-
version of highly aggregated epithelial cells to migratory
and invasive cells. In the EMT conversion, E-cadherin is
suggested to be an important player due to its functions
in homophilic interaction with the adjacent cells and the
observation that its expression is frequently lost in epithelial
cancers with themigratory phenotype [19]. Epithelial cells are
anchorage-dependent cells in which the growth and survival
are dependent on extracellular matrix adhesion. When the
normal epithelial cell loses cellular contact with the ligands
in the extracellular matrix, it will undergo a specific type of
programmed cell death (i.e., anoikis) triggered by multiple
protein kinases/phosphatase including phosphoinositide-3
kinase (PI3K), extracellular signal-regulated kinase (ERK),
and JunN-terminal kinases (JNKs) [20]. Epithelial cancer cell
undergoing EMT will acquire a fibroblast-like morphology
with a high motile phenotype [21]. Apart from physical
alterations, E-cadherin could induce EMT by induction of
transcription factor such as Twist [21]. Twist is usually
associated with the advanced cancers and linked with the
positive lymph node, lung metastasis, and poor survival of
oral squamous cell carcinoma patients [22].
4. Epigenetic Control of Gene Expression
Epigenetic regulation refers to control of gene expression
without the reliance on DNA sequence [23]. The most
common form of epigenetic regulation includes changes in
the CpG island methylation patterns in the promoter region
via addition of an aberrant methyl group to the cytosine
residue, remodeling of the chromatin structure viamodifying
the histone protein core, and control of the expression level
with the negative transcription regulator, microRNA. In
terms of the epigenetic control of E-cadherin expression in
the head and neck cancers, the most frequently reported
mechanism includes promoter DNA hypermethylation and
overexpression of the target microRNA.
5. Epigenetic Control of E-Cadherin
Expression by DNA Methylation
Germline and somatic mutation of E-cadherin gene has been
found in diffuse-type gastric cancer, colorectal cancer, lobular
and invasive ductal breast cancer, endometrial ovarian cancer,
andprostate cancers [12]. Although loss of E-cadherin expres-
sion is also common in head and neck cancer, especially in
the metastatic tumors, genetic abbreviation in head and neck
cancers is relatively rare. In contrast, the most common form
of E-cadherin alterations in head and neck cancer is DNA
methylation.
DNA methylation refers to the covalent addition of a
methyl group to the cytosine residue in the CpG dinu-
cleotide [24]. Methyl CpG dinucleotide in fact is distributed
throughout the normal genome. In cancer, however, methyl
CpG cluster (CpG islands) embedded in the regulatory
regions of the tumor-related genes becomes methylated by
the de novo DNA methyltransferases (DNMTs). The dense
methylation incidence in the CpG islands is referred to as
DNA hypermethylation which will lead to transcriptional
silencing of the associated genes [25, 26]. Methylated DNA
sequence will allow the preferential binding of methylated
DNA binding proteins (e.g., MeCP2 and MBD2) and histone
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Figure 1: E-cadherin promoter region contains dense CpG dinu-
cleotide density.
deacetylases leading to the nucleosome remodeling and
histone modification and thereby hindering the accessibility
of the transcription machinery [23].
6. Promoter Hypermethylation of E-Cadherin
Promoter hypermethylation is a potential epigenetic mech-
anism to the E-cadherin gene due to the dense CpG
dinucleotide density in the transcription regulatory region
(Figure 1). In cancer cell lines which grew as monolayer,
treatment of the E-cadherin methylated cell lines with
demethylating agent such as 5-azacytidine can restore the
transcription and reverse the invasive phenotype [18]. How-
ever, the reversion with demethylation is not effective in all
cases suggesting that other mechanisms exist in silencing E-
cadherin at transcription level in the head and neck cancer
cells [27]. Methylation of 5󸀠 promoter region of the E-
cadherin is found to be an early event in oral cancer lesions
[28]. The presence of E-cadherin methylation is independent
of the invasive and metastatic potential of the cancer cells
[29]. At first, methylated DNA is thought as a specific cancer
marker as the de novomethylated sequence is found largely in
the cancerous tissue. In addition, the methylated E-cadherin
DNA is present in the peripheral blood and oral rinse of head
and neck cancer patients leading to the suggestion of using it
as an noninvasive diagnostic marker in head and neck cancer
detection.This potential use has also been explored in the oral
rinse collected from oral squamous cell carcinoma patients
[30]. However, before moving to the clinical use, it should
be considered that methylated E-cadherin could possibly be
deposited in the noncancerous epithelia in the head and neck
region. Using pyrosequencing, the existence of methylated E-
cadherin DNA is demonstrated in both oral squamous cell
carcinoma and normal tissues obtained from the resection
margin of the same patients with no statistical difference [31].
7. E-Cadherin Hypermethylation Induced by
Human Papilloma Virus (HPV)
De novo methylation of E-cadherin DNA could be induced
by external factors such as virus infection. HPV infection
is particularly common in oropharyngeal carcinoma and
is considered as an independent risk factor [32, 33]. HPV
positive tumor demonstrated characteristic features in epi-
demiology, clinical behavior, andmolecular presentation and
is regarded as a distinctive entity in head and neck cancer
management [34, 35]. In the context of DNA methylation
patterns, head and neck cancer infected with HPV has dis-
tinctive methylation imprints in comparison with the HPV
negative counterparts [36]. The corresponding methylation
pattern mediated by HPV infection is sometime referred to
as methylation signature or methylator phenotype of head
and neck cancers, in which high frequency of E-cadherin
DNAmethylation is observed and supports the idea thatHPV
facilitates E-cadherin suppression via altering the methylated
CpG imprinting [36].
8. Epigenetic Controls of
Gene Expression with MicroRNA
MicroRNA is a group of highly conserved noncoding RNA
molecules with size that usually ranged from 20 to 22 b.p.
long [37]. It was first identified in Caenorhabditis elegans
(C. elegans) and is now recognized as a kind of epige-
netic regulator in cell growth, proliferation, morphogenesis,
tissue remodeling, and development. Precursor microRNA
is transcribed by RNA polymerase II and modified by
the RNase III-type nuclease, Dorsha, in the nucleus to
form the primary microRNA. Primary microRNA will later
be transported into the cytoplasm by Exportin-5 (a Ras-
GTP-dependent dsRNA-binding protein) and cleaved by
Dicer (RNase complex) and TRBP [TAR (transactivation-
responsive RNA of HIV-1) RNA-binding protein] to gener-
ate the mature microRNA. Mature microRNA functions as
translation inhibitor by hindering the translation machinery
or promoting the recruitment ofArgonaute-containingRNA-
induced silencing (RISC) complex after binding to the target
mRNA via a partial/incomplete complementary binding.
The matching between the seed sequence (2–7 b.p.) of the
microRNA with the target mRNA sequence would suffice to
initiate the regulation cascade bymicroRNA [38].MicroRNA
expression patterns are tissue-specific. Increasing evidence
suggested that head and neck cancers have a distinctive
microRNA expression pattern which account for the char-
acteristic clinical features of head and neck cancers [39].
Theoretically, the microRNA profile is highly correlated with
the gene expression patterns displayed by the head and
neck cancer cells as microRNA could directly control the
translation of their target mRNA transcripts leading to the
reduction in protein expression [39].
9. Potential Linkage between E-Cadherin and
MicroRNA Networks
In comparison with DNA methylation which modify the E-
cadherin gene sequence directly, microRNAs regulated the
expression of E-cadherin by targeting different transcription
or transcription-associated factors linkingwith the transcrip-
tional processes including NF-𝜅B1, ZEB1, ZEB2, EP300, and
PTTG1 (Figure 2).
9.1. MicroRNA-9. MicroRNA-9 expression is activated by
the MYC/MYCN signaling cascade and triggers EMT by
targeting E-cadherin mRNA [40]. In c-myc-induced mouse
mammary tumors, a significant increase in microRNA-9 is
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Figure 2: MicroRNAs regulate the expression of E-cadherin by
targeting multiple transcription regulators.
observed [40]. MicroRNA-9 is classified as tumor suppress-
ing microRNA, as reduction in microRNA-9 expression by
DNA methylation is found in the oral, oropharyngeal, and
laryngeal carcinoma [41, 42]. Overexpressing microRNA-9
in the aggressive oral squamous cell carcinoma cell lines
suppresses the invasion ability [42]. The microRNA-9 con-
tains the seed sequence targeting the 3󸀠-untranslated region
(UTR) of NF-𝜅B1 and therefore suppressed the function of
E-cadherin repressor, Snail1 [43].
9.2. MicroRNA-10b. Distinct from other head and neck
cancers, nasopharyngeal carcinoma is consistently associated
with Epstein-Barr virus (EBV) infection. EBV is found nearly
in all the World Health Organization (WHO) type II and
type III nasopharyngeal carcinomas. E-cadherin expression
in nasopharyngeal carcinoma is controlled by Twist (a highly
conserved transcription factor of the basic helix-loop-helix
protein) via theWnt signaling cascade [44]. Twist is involved
in the invasion and metastasis of nasopharyngeal carcinoma
and is closely correlated with the regional lymph node
status of the nasopharyngeal carcinoma patients [45]. The
increase in Twist expression is induced by one of the viral
oncoprotein, latentmembrane protein 1 (LMP1), in the cancer
cells. Recently, it was noticed that Twist also controls E-
cadherin by inducing microRNA-10b expression [46]. NPC
cells overexpressing microRNA-10b demonstrated lower E-
cadherin expressionwith highermobility [47].Themigration
inducing effects is demonstrated in the mouse bone marrow-
derived mesenchymal stem cells with microRNA-10b [48]. In
addition, the viral protein LMP1 could also be a modulator
of microRNA-10b in the nasopharyngeal carcinoma cells
[49].
9.3. MicroRNA-31. Compared with the normal oral mucosa,
high microRNA-31 expression is found in the oral poten-
tial malignant disorder (OPMAD) tissues suggesting that
microRNA-31 is a candidate oncogenic microRNA involved
in the early development of oral tongue cancers [50]. Ectopic
expression of microRNA-31 could promote the growth and
immortalization of the nontumorigenic oral keratinocytes
[50]. In a three-dimensional organoid culture derived from
colon carcinoma, increase in microRNA-31 expression is
observed during EMT induced by transforming growth
factor 𝛽, a proinvasion/metastasis inducer [51]. Treatment
of the cancer cells with transforming growth factor 𝛽 could
induce E-cadherin redistribution from the cell surface to
cytoplasm without affecting the expression level [51]. In oral
mucosa, E-cadherin redistribution from membrane to the
cytoplasm is observed during EMT [52].
9.4. MicroRNA-192. MicroRNA-192 is overexpressed in the
supraglottic laryngeal cancer patients with cervical lymph
node metastasis [53]. Overexpression of miR-192 in the prox-
imal tubular cells could suppress the expression of both the
2 major E-cadherin suppressors: ZEB1 (TCF8/deltaEF1) and
ZEB2 (SMAD-interacting protein 1 [SIP1]/ZFXH1B) [54].
They are E-box binding transcription factors associated with
the EMT initiation in epithelial cells by repressing epithelial
differentiation and cell-cell adhesion [55, 56]. The inverse
correlation of ZEB1 with E-cadherin leads to the loss of
intercellular adhesion. Further, it is suggested that ZEB1 is
linked with the cancer cell dedifferentiation and cell polarity
[55].
9.5. MicroRNA-200 Family. ThemicroRNA-200 family cons-
ists of 5 members: microRNA-141, microRNA-200a, micro-
RNA-200b, microRNA-200c, and microRNA-429. Micro-
RNA-200 family is associated with the invasive phenotype
of multiple human cancers [57]. In oral tongue squamous
cell carcinoma, expression of the microRNA-200 family
members is controlled by DNA methylation. Activation
of microRNA-200a, microRNA-200b, microRNA-429, and
microRNA-200c is closely correlated with the global CpG
methylation reduction. It is suggested that miR-200 family
controls E-cadherin at transcription level by targeting the E-
cadherin E-box repressors ZEB1 and ZEB2 [58, 59]. In the
mouse model, microRNA-200c is a positive regulator of E-
cadherin.MicroRNA-200c can induce E-cadherin expression
[60]. Reversely, deletion of microRNA-200c results in E-
cadherin downregulation [60]. Apart from the ZEB, micro-
RNA-200 could also regulate E-cadherin expression by tar-
geting the transcription coactivator of E-cadherin, EP300
[61, 62]. The E1A-associated cellular p300 is a positive E-
cadherin regulator protein and functions by binding to
the two p300 binding sites located within the E-cadherin
regulatory sequence [63]. Of the 5 miR-200 family members,
microRNA-200b andmicroRNA-200c are suggested to be the
regulators of E-cadherin through targeting p300 transcripts
in the cancer cells [61].
9.6. MicroRNA-205. MicroRNA-205 is expressed at a high
level in normal tissue containing squamous epithelium [64].
In head and neck squamous carcinoma, high microRNA-
205 is also observed, especially in case when positive lymph
node is detected [64]. In contrast, in laryngeal squamous cell
carcinoma, microRNA-205 is significantly downregulated in
the primary cancer tissues and cell line [65]. MicroRNA-
205 could target ZEB2 mRNA and hence repress E-cadherin
expression in the cancer cells [66].
9.7. MicroRNA-655. Apart from microRNA-200 family, the
E-cadherin suppressor ZEB1 is controlled by another EMT-
relatedmicroRNA,microRNA-655. Reduction ofmicroRNA-
655 expression has recently been reported in the oral
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squamous cell carcinoma [67]. Overexpressing microRNA-
655 could suppress the invasion and migration of the can-
cer cell lines together with the induction of E-cadherin
expression [67]. In esophageal squamous cell carcinoma,
microRNA-655 could inhibit tumor cellsmigration via target-
ing pituitary tumor-transforming gene-1 (PTTG1), an inva-
sion and migration promoter. In breast cancer cells, PTGG1-
overexpressing cells have spindle shape with reduction in E-
cadherin expression [68]. In addition, expression levels of
EMT markers (including N-cadherin and vimentin) were
induced in the PTGG1-expressing cells.
10. Cancer Cells Interact with the
Environmental Perturbation by Regulating
Their MicroRNA Expression Patterns:
The Role of Hypoxia-Related MicroRNA
Intratumoral hypoxia is a result from the poor vasculature
formed in the rapid proliferating cancer leading to the
development of a microenvironment with low oxygen envi-
ronment.The abnormality in the tumormicrovasculaturewill
increase the diffusion distances leading to the disturbance of
gas exchange. Consequently, the oxygen transport capacity of
the blood in the tumor bulk will be reduced as the tumor
grows [69]. With the deteriorating gas exchange condition,
normal tissues will be subjected to cellular quiescence, differ-
entiation, and apoptosis leading to the impairment of growth
and development [70]. In order to survive, cancer cells must
tolerate the oxygen-deprived environment by switching their
gene expression patterns to adapt the anaerobic condition
[71]. Tumor cells with the ability to survive and adapt under
the adverse condition are selected through clonal expan-
sion with aggravate aggressiveness and genomic changes
[69, 70].
Under hypoxic condition, one hallmark feature of head
and neck cancer is the increase in invasiveness with enhance-
ment of EMT ability with altering E-cadherin expression pat-
terns [72]. It is suggested thatHIF-1 could regulate E-cadherin
indirectly by controlling the expression of E-cadherin regula-
tors [72, 73]. With our understanding of the microRNA reg-
ulatory mechanism, it is now recognized that this is achieved
by hypoxia-inducible factor-1 (HIF-1), which modulates the
microRNAproductionmachinery subsequently in the cancer
cells in response to the low-oxygen microenvironment. In
view of the emerging role of microRNA in gene regulation,
several groups suggested that the hypoxic condition or HIF-1
itself could function as a microRNA regulator in controlling
specific microRNA expression under the adverse condition.
For example,microRNA-210, a tumor suppressingmicroRNA
in head and neck cancers, is suggested to be a responsive
element to the hypoxic stress and the expression is controlled
by HIF-1 [74]. As E-cadherin expression is also controlled
by HIF-1 under hypoxic condition, it remains to be explored
whether HIF-1 could also control E-cadherin by induc-
ing specific microRNA expression. Recent data suggested
that microRNA could be the upstream regulator of HIF-1.
MicroRNA-31, for instance, can regulate HIF-1 expression
in head and neck squamous cell carcinoma by controlling
its regulator factor-inhibiting hypoxia-inducible factor (FIH)
under normoxic condition [75]. Another example is the E1A-
associated cellular p300 transcriptional coactivator (EP300).
As mentioned above, the transcription coactivator EP300
(regulated by themiR-200 family) is an inducer of E-cadherin
expression on the one hand. On the other hand, it is also a
transcription activator of HIF-1A (hypoxia-inducible factor-
1 alpha). This has led to the suggestion that the HIF-1A and
microRNA-210 family are intimately linked and cooperated
in controlling E-cadherin expression under hypoxic condi-
tion.
11. Conclusions
E-cadherin expression in the head and neck epithelium is
essential for the morphogenesis and homeostasis of epithelial
tissues. Reduced E-cadherin expression has been observed
in head and neck cell lines, animal xenograft model, and
primary tumor of head and neck cancer. Decreased E-
cadherin expression in the primary tumor is linked with the
invasiveness of the cancers cells. Low E-cadherin expression
is associated with poor prognostic factor of overall survival
and late cervical metastasis in head and neck cancer patients.
E-cadherin is suggested to be an important player in EMT, a
process in which epithelial head and neck cancer cells acquire
the ability to migrate and invade the surrounding tissues.
The expression of E-cadherin was under epigenetic controls:
promoter hypermethylation and microRNA. Environmental
perturbation such as hypoxic condition and HPV infection
could also regulate the expression of E-cadherin via affecting
hypoxia-related microRNA or promoter methylation. Vari-
ous microRNAs regulated the expression of E-cadherin by
targeting genes involved in the transcription process includ-
ing NF-𝜅B1, ZEB1, ZEB2, EP300, and PTTG1. In light of the
regulatory network between microRNAs and E-cadherin, it
is feasible to reintroduce the expression of E-cadherin via
microRNA-based therapy aiming at controlling the regional
and distant metastasis of head and neck cancers. A more
comprehensive understanding of the regulatory mechanisms
is required for the clinical use of microRNAs to modulate E-
cadherin expression in the clinical settings.
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